PARTNERS GROUP PRIVATE EQUITY LIMITED

Monthly report as of 30 September 2024



NAV increases by 0.5% in September

- NAV increased by 0.5% to EUR 14.24 per share
- Positive value creation (0.9%) partially offset by adverse currency movements (-0.3%)
- KinderCare, the fifth largest portfolio company in PGPE Ltd, was the largest contributor to the NAV increase following its IPO pricing
- PGPE Ltd invested EUR 6.7 million and received distributions of EUR 6.3 million


In September, PGPE Ltd invested EUR 6.7 million, of which EUR 5.5 million was in FairJourney Biologics, a leading European antibody discovery Contract Research Organization (CRO) based in Porto, Portugal. Founded in 2012, FairJourney provides services for the discovery, engineering, production, and characterization of antibodies. FairJourney has worked with over 250 clients across the globe to develop more than 4,000 unique screening libraries for identifying antibodies. The company's partnerships with its customers have yielded 14 therapies that are currently in active clinical development to treat unmet patient needs across oncology, immunology, and cardiovascular disease. FairJourney is set to benefit from structural market tailwinds, including increased R&D spend, outsourcing trends, and a favorable regulatory landscape. Partners Group will work with management on a value creation plan for FairJourney that will expand its technology and capabilities through organic and inorganic investment to unlock faster, more effective drug development for its partners.

PGPE Ltd received distributions totaling EUR 6.3 million, with EUR 6.0 million coming from the sale of a portion of its stake in Galderma, a pure-play dermatology category leader. The shares were sold to L'Oréal, via an off-market block trade that saw the French beauty and cosmetics group invest for a 10% stake in Galderma. The two companies have also agreed on a scientific partnership to develop advanced, future-proof technologies with direct applications in the field of dermatology.

Key figures		
In EUR	31.08.2024	30.09.2024
NAV per share	14.17	14.24
Share price	11.25	10.65
Discount to NAV	-20.6%	-25.2%
Portfolio (in million)	1'007.72	1'015.18
Net asset value (in million)	979.55	984.62
Cash and cash equivalents (in million)	5.01	5.40
Undrawn credit facility (in million)	140.00	140.00
Dividend LTM	0.72	0.72
Dividend yield	6.4%	6.8%

Key figures in GBP		
In GBP	31.08.2024	30.09.2024
NAV per share	11.93	11.85
Share price	9.66	8.80

NAV performance (total return)



■ PGPE Ltd Performance (RHS)

Total return in EUR (%)				
	YTD	1 year	3 years	5 years
PGPE Ltd NAV	3.1	-1.0	2.8	43.4
PGPE Ltd share price	5.9	6.8	-6.0	41.5

Largest ten	direct investments			
			%	of NAV
1. PCI F	Pharma Services	NAM	Healthcare	8.1
2. Emer	ria	WEU	Real Estate Services	5.4
3. Amm	nega	WEU	Industrials	5.3
4. Visha	al Mega Mart	APC	Consumer discretionary	n.a.
5. Kind	erCare Learning Companies	NAM	Consumer discretionary	4.9
6. Diver	rsiTech	NAM	Industrials	4.2
7. Tech	em Metering GmbH	WEU	Industrials	3.8
8. Intern	national Schools Partnership	WEU	Consumer discretionary	3.5
9. Breit	ling	WEU	Consumer discretionary	2.8
10. Clari	0	NAM	Healthcare	2.7

Monthly NAV performance (total return)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2015	2.6%	0.8%	2.8%	-1.5%	1.4%	3.4%	-0.3%	-0.4%	3.9%	0.5%	0.7%	2.5%	17.5%
2016	-1.1%	0.1%	1.2%	2.0%	2.1%	1.3%	0.0%	2.1%	1.8%	0.3%	0.6%	1.8%	12.9%
2017	1.0%	2.1%	2.7%	1.1%	0.0%	1.6%	-0.4%	-0.2%	1.8%	0.4%	-0.5%	1.1%	11.2%
2018	0.2%	1.0%	0.7%	0.8%	0.2%	2.7%	1.1%	0.2%	2.1%	-0.6%	-0.2%	-1.6%	6.8%
2019	0.7%	1.8%	3.0%	0.6%	0.8%	2.3%	0.4%	-0.2%	4.2%	-0.4%	0.5%	5.7%	21.1%
2020	0.2%	-1.0%	-14.1%	5.6%	3.0%	2.9%	2.3%	3.1%	3.8%	-0.8%	3.1%	3.1%	10.0%
2021	0.1%	0.9%	7.3%	1.5%	1.2%	4.8%	0.6%	1.1%	0.9%	0.8%	-0.4%	-0.8%	19.4%
2022	-0.8%	-0.8%	1.7%	-0.6%	-1.3%	-5.8%	2.3%	0.3%	1.0%	-1.3%	0.5%	3.4%	-1.6%
2023	0.7%	0.4%	0.3%	0.1%	2.0%	0.0%	0.8%	0.6%	0.9%	-1.0%	-0.9%	-2.1%	1.8%
2024	0.8%	-0.8%	3.6%	-0.1%	-0.7%	1.3%	-0.7%	-0.8%	0.5%				3.1%

PARTNERS GROUP PRIVATE EQUITY LIMITED

Monthly report as of 30 September 2024



Partners Group Private Equity Limited (PGPE Ltd or the Company) is an investment holding company listed on the London Stock Exchange. The Company's investment objective is to provide shareholders with long-term capital growth and an attractive dividend yield by investing in a global portfolio of private companies. PGPE Ltd is managed in its investment activities by Partners Group, a global private markets investment management firm with USD 149 billion in investment programs under management in private equity, private debt, private real estate and private infrastruc-

Information

For further information please visit: www.partnersgroupprivateequitylimited.com

Investor Relations

Phone: +44 (0) 1481 711 690 Fax: +44 (0) 1481 730 947 pgpe-ltd@partnersgroup.com


Registered Office

Partners Group Private Equity Limited **Tudor House** P O Box 477 Guernsey, GY1 6BD

Key facts	
Stock exchange	London
Reuters Euro Quote	PEY.L
Reuters Sterling Quote	PEYS.L
Bloomberg Euro Quote	PEY LN
Bloomberg Sterling Quote	PEYS LN
ISIN (Euro and Sterling Quote)	GG00B28C2R28
Sedol Euro Quote	B28C2R2
Sedol Sterling Quote	BF012D4
Product life start date	12.05.1999
Shares outstanding	69'151'168


Portfolio composition

Investments by regional focus




Α	Europe	45%
В	North America	44%
С	Asia-Pacific	8%
D	Rest of World	3%

Investments by stage



Α	Buyout Small/Mid-cap	58%
В	Buyout Large-cap	38%
С	Other	4%

Economic currency exposure



Α	EUR	50%
В	USD	38%
С	CHF	5%
D	INR	3%
Е	GBP	3%
F	Other	1%

